Epigenetic Mechanisms in Leukemias and Lymphomas

Area of Science:

• Hematology
• Cancer Biology
• Epigenetics

Background:

• Aberrant epigenetic programming is a hallmark of hematologic malignancies, including acute myeloid leukemia (AML) and B-cell lymphomas.
• Despite arising from the hematopoietic system, these malignancies exhibit distinct epigenetic mechanisms.
• Somatic mutations in transcription factors and epigenetic modifiers commonly disrupt the epigenome in these cancers.

Purpose of the Study:

• To highlight the role of epigenetic dysregulation in myeloid and lymphoid neoplasms.
• To discuss the potential of epigenetic therapies for hematologic malignancies.
• To emphasize the complexities in targeting the epigenome for effective cancer treatment.

Main Methods:

• Review of current understanding of epigenetic regulation in hematologic malignancies.
• Analysis of the impact of somatic mutations on the epigenome.
• Discussion of emerging epigenetic therapeutic strategies.

Main Results:

• Myeloid and lymphoid neoplasms display epigenetic allele diversity, enhancing tumor cell fitness.
• Commonly mutated genes in these cancers involve transcription factors and epigenetic modifiers, leading to widespread epigenome disruption.
• Epigenetic therapies represent a promising avenue for treating these blood cancers.

Conclusions:

• Effective epigenetic therapies require restoring multiple layers of epigenetic marks and ensuring specificity.
• Understanding the diverse epigenetic mechanisms driving different hematologic malignancies is crucial.
• Targeting the epigenome holds significant potential for improving patient outcomes in AML and lymphomas.